Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.83 |
| ▸ | DRD4 | P21917 | 3/20 | 0.77 |
| ▸ | CCR3 | P51677 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.65 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panuramine SCHEMBL9749426 | 0.99 | MCHR1 (0.81) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL9592451 | 0.92 | DRD4 (0.71) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL11057431 | 0.92 | CCR3 (0.84) | MCHR1DRD4CCR3 | |
| SCHEMBL9592427 | 0.92 | MCHR1 (0.70) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL9792346 | 0.92 | MCHR1 (0.84) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL9593277 | 0.90 | MCHR1 (0.81) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL9594285 | 0.90 | DRD4 (0.75) | MCHR1DRD4CCR3 | |
| SCHEMBL9592647 | 0.90 | MCHR1 (0.70) | MCHR1DRD4CCR3SIGMAR1 | |
| SCHEMBL9590523 | 0.89 | DRD4 (0.67) | MCHR1DRD4CCR3SIGMAR1SLC6A12 | |
| SCHEMBL9601120 | 0.89 | MCHR1 (0.80) | MCHR1DRD4CCR3SIGMAR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4536231-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2025-04-16 | — | — | EP | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2023235937-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2023-12-14 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| US-20230313301-A1 | METHODS OF IDENTIFYING AUTISM SPECTRUM DISORDER | WASHINGTON STATE UNIVERSITY | 2023-10-05 | — | — | US | claimed |
| EP-4185712-A2 | METHODS OF IDENTIFYING AUTISM SPECTRUM DISORDER | Washington State University (US) | 2023-05-31 | — | — | EP | claimed |
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | ATLAS PHARMACEUTICALS BV (BE) | 2022-08-25 | — | — | US | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2016106182-A1 | DEVICES, SYSTEMS AND METHODS FOR TREATING UROLOGICAL AND GASTROINTESTINAL DISORDERS BY ELECTRICAL STIMULATION OF THE FOOT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0035374-B1 | PIPERIDYL - UREA, - THIOUREA AND - GUANIDINE DERIVATIVES, AND INTERMEDIATES THEREFOR, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-01-30 | — | — | EP | claimed |
| EP-0035374-A2 | Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | HTR5A, HTR1A, HTR4 | MCHR1 21/4885DRD4 68/4885CCR3 4531/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | MCHR1 87/4885DRD4 17/4885CCR3 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.